Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune is well-positioned for success with numerous development and commercialization partnerships, strong preliminary data for PD treatment and detection, and a well-developed pipeline targeting multiple neurodegenerative diseases. Despite a decrease in R&D expenses, the company is still able to maintain a healthy cash position. With a strong focus on precision medicine and a versatile platform, AC Immune has the potential to make significant strides in the treatment and detection of neurodegenerative diseases.

Bears say

AC Immune is heavily focused on targeting neurodegenerative diseases through its therapeutic and diagnostic products, but many of these are still in early stages of testing and have not yet proven their efficacy. This has resulted in a long timeline for potential readouts and delayed potential revenue. Additionally, there are concerns about the safety and effectiveness of their vaccines compared to traditional mAbs, which may limit their success in the increasingly competitive AD treatment market. Finally, their financials show consistently negative earnings and a high cash burn rate, indicating potential financial struggles down the line.

AC Immune (ACIU) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 1 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.